Department of Medicine and Center For Liver Disease, Inova Fairfax Hospital.
Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA.
J Clin Gastroenterol. 2020 May/Jun;54(5):459-467. doi: 10.1097/MCG.0000000000001172.
The main purpose of this study was to assess the recent trends in mortality and health care utilization of hepatocellular carcinoma (HCC) among Medicare population in the United States.
The incidence of HCC is increasing in the United States.
Data were obtained for a sample of Medicare beneficiary from 2005 to 2014. Diagnosis of HCC and etiology of liver disease were based on ICD-9 codes. Temporal trends in HCC rates, clinical, demographical and utilization parameters were analyzed by joinpoint regression model.
Study cohort included 13,648 Medicare recipients with HCC (mean age: 70.0 y, 62.8% male and 76.0% white). Non-alcoholic fatty liver disease (NAFLD) was the most common cause of HCC in the inpatient (32.07%) and outpatient (20.22%) followed by hepatitis C virus (HCV) (19.2% and 9.75%, respectively). Between 2005 and 2014, HCC rate per 100,000 Medicare recipients increased from 46.3 to 62.8 [average annual percentage change (AAPC) =3.4%, P<0.001]. Rate of HCV-HCC increased from 6.18 to 16.54 (AAPC=11.8%, P<0.001) while the NAFLD-HCC increased from 9.32 to 13.61, P<0.001). Overall 1-year mortality decreased from 46.2% to 42.1% (AAPC=-1.7%, P=0.004). Total charges increased from $67,679 to $99,420 (AAPC=5.1%, P<0.001) for inpatients and from $11,933 to $32,084 (P<0.001) for outpatients. On comparison of patients with hepatitis B virus-HCC, those with NAFLD-HCC (odds ratio: 1.87, P<0.001) had higher risk of mortality. On comparison of patients with hepatitis B virus-HCC, those with HCV-HCC had higher charges (percent change: 24.33%, 95% confidence interval: 1.02%-53.02%, P=0.040).
Although HCC rates are increasing, the overall mortality is decreasing. NAFLD is the most important cause of HCC and an independent predictor of HCC in the outpatient setting for Medicare patients with HCC.
本研究的主要目的是评估美国医疗保险人群中肝细胞癌(HCC)死亡率和医疗保健利用的近期趋势。
HCC 的发病率在美国呈上升趋势。
从 2005 年至 2014 年,对医疗保险受益人的样本数据进行了分析。HCC 的诊断和肝病病因基于 ICD-9 代码。使用 Joinpoint 回归模型分析 HCC 发生率、临床、人口统计学和利用参数的时间趋势。
研究队列包括 13648 名患有 HCC 的 Medicare 受助人(平均年龄:70.0 岁,62.8%为男性,76.0%为白人)。非酒精性脂肪性肝病(NAFLD)是住院(32.07%)和门诊(20.22%)中 HCC 的最常见病因,其次是丙型肝炎病毒(HCV)(分别为 19.2%和 9.75%)。2005 年至 2014 年间,每 100000 Medicare 受助人的 HCC 发生率从 46.3 增加到 62.8 [平均年百分比变化(AAPC)=3.4%,P<0.001]。HCV-HCC 的发生率从 6.18 增加到 16.54(AAPC=11.8%,P<0.001),而 NAFLD-HCC 的发生率从 9.32 增加到 13.61,P<0.001)。总的 1 年死亡率从 46.2%下降到 42.1%(AAPC=-1.7%,P=0.004)。住院患者的总费用从 67679 美元增加到 99420 美元(AAPC=5.1%,P<0.001),门诊患者的费用从 11933 美元增加到 32084 美元(P<0.001)。与乙型肝炎病毒-HCC 患者相比,NAFLD-HCC 患者的死亡率更高(比值比:1.87,P<0.001)。与乙型肝炎病毒-HCC 患者相比,HCV-HCC 患者的费用更高(百分比变化:24.33%,95%置信区间:1.02%-53.02%,P=0.040)。
尽管 HCC 发病率呈上升趋势,但总体死亡率正在下降。NAFLD 是 HCC 的最重要病因,也是 Medicare 肝癌患者门诊环境中 HCC 的独立预测因素。